SI
SI
discoversearch

Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
2386 94 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Regeneron (REGN) is a biotech working in recombinant DNA technology. Until '94 it generally traded between 10 and 20 dollars until the FDA beat it up on it's treatment for Lou Gehrig's Disease. While it was trading at the $4 level at the end of '94, the former chairman of Merck(I believe) took the helm and the stock climbed back to about 11, then traded between 11 and 14. In late May, Option volume increased, news about a discovery concerning muscles was announced, and the stock has risen sharply to Friday, May 24 '96 close of 18.875.

Historically, the stock has failed around 22. Yet AMGEN has more than a 17.7% stake with warrants to increase it's stake to 20%, at 16$ per share. Could this be the time it breaks out?
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2386Novartis 1Q report: Lucentis ex-US sale of $520m, 17% growth v 1Q2017 (10% grow Miljenko Zuanic-Thursday
2385Medicare part B, is price control for biologic advancing? politico.com <AnoMiljenko Zuanic-Monday
2384 This may help: seekingalpha.comMiljenko Zuanic-April 11
2383Why REGN/SNY can not do something like this???? clinicaltrials.gov (BGNE-PD1 hmMiljenko Zuanic-April 10
2382This would be nice addition to Kevzara, but they are so SLOW: medpagetoday.com Miljenko Zuanic-April 7
2381They need break true with additional drug (like Eylea), but not splitting US-shaMiljenko Zuanic1April 7
2380I think the company is fine just that the stock price will be stagnant for some Felix B-April 7
2379< It would have to be something huge and unexpected like large Kevzara or PraMiljenko Zuanic-April 7
2378At this point, I don't think anything will move the needle. It would have tFelix B-April 6
2377RE: Dupi 1Q US sale Based on TRx/BNRx numbers, I am projecting 1Q sale at ~$175Miljenko Zuanic1April 6
2376Must be severity, look at Soliris and they get no pushback. Then again humira hFelix B-April 5
2375Continuation of the same story in EU, starting with UK: fiercepharma.com Is it Miljenko Zuanic-April 3
2374One way or another, it will not be "overnight" development.Miljenko Zuanic-April 2
2373I mean any of their external collaborations (Decibel, ANLY, etc), curious what wFelix B-April 1
2372Happy Easter to all, who celebrate. No, as far as I know. It is platform collabMiljenko Zuanic-April 1
2371Thanks for sharing. Curious if any of the recent external collaborations pan ouFelix B-March 31
2370Yan in Nature Reviews: readcube.comMiljenko Zuanic1March 30
2369One simple comment on today ESPR's BA result in P2: After well(???) executeMiljenko Zuanic-March 27
2368Chiron patent is from 1984!Miljenko Zuanic-March 24
2367NVS has nothing to lose by trying, other than some modest legal expenses.DewDiligence_on_SI-March 24
2366Very desperate.Felix B-March 24
2365Desperate action by Novartis, lifesciencesipreview.comMiljenko Zuanic-March 23
2364Dupi continue with "troubled" trajectory. Market penetration is slow, Miljenko Zuanic-March 23
2363Yes, it was. They only validated target, by confirming LofF mutation outcome. OtMiljenko Zuanic-March 22
2362This was already known as a NASH target. Zhu Y, Imperato-McGinley JL (9 NovemBiotech Jim-March 21
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2018 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.